- EASL results: HepC developers seeking shorter treatments
- Reading between the lines of J&J's $1.75bn Alios buy
- Achillion, Regulus chase shorter HCV regimens, but can they beat Gilead?
- AASLD data confirm Gilead as ultimate hep C champion
ANALYSIS Other Informa Analysis
- INTERVIEW: Champions Oncology champions personalized tumor models
- PROFILE: AstraZeneca's Mene Pangalos on yin and yang, not believing your own press, and his part in Soriot's vision